Toronto general Hospital_Site Number :1240002
Welcome,         Profile    Billing    Logout  
 10 Trials 
25 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cheung, Angela M
NCT01896011: Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures

Completed
3
34
Canada
Teriparatide 20 mcg, Brand name Forteo, Placebo
University Health Network, Toronto, The Physicians' Services Incorporated Foundation, Eli Lilly and Company
Non Displaced Atypical Femoral Fractures
12/21
12/22
PRECIOSA, NCT03451292 / 2016-001789-28: Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites

Completed
3
410
Europe, Canada, US, RoW
Albutein 20% Injectable Solution, Standard medical treatment
Grifols Therapeutics LLC, Instituto Grifols, S.A.
Decompensated Cirrhosis and Ascites
05/24
05/24
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
01/25
ESSOR, NCT05999435: Study of LAU-7b for the Treatment of Long COVID in Adults

Active, not recruiting
2/3
272
Canada
LAU-7b for 3 cycles, fenretinide, LAU-7b for 1 cycle, then placebo, Placebo for 3 cycles, sugar pill
Laurent Pharmaceuticals Inc.
Long COVID
08/24
10/24
RECLAIM - HBOT, NCT06452095: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy for the Treatment of Post COVID Condition

Not yet recruiting
2/3
120
NA
Hyperbaric Oxygen therapy
University Health Network, Toronto
Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19
12/28
12/28
RECLAIM, NCT05513560: Recovering from COVID-19 Lingering Symptoms Adaptive Integrative Medicine

Suspended
2/3
460
Canada
Ibudilast, MN-166, Pentoxifylline, Placebo
University Health Network, Toronto
Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19
05/26
12/26
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
Hi-OXSR, NCT06379620: Pilot Open Label Use of the for the Treatment of Post COVID-19 Cognitive Dysfunction

Completed
1
37
Canada
Hi-OxSR Sequential Rebreathing mask (oxygen concentrator)
University Health Network, Toronto
Post COVID-19 Condition
03/24
03/24
NCT05231668: Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Terminated
1
16
Europe, Canada, US, RoW
SAR439459, Placebo
Sanofi
Osteogenesis Imperfecta
11/24
11/24
NCT01155245: Teriparatide (PTH) and Bone Strength in Postmenopausal Women

Active, not recruiting
N/A
60
Canada
Forteo
University Health Network, Toronto, Eli Lilly and Company
Osteoporosis
01/24
01/25
NCT01747304: Evaluation of IVA (SE Femur Scans) to Identify Incomplete AFFs

Recruiting
N/A
500
Canada
DXA Se femur scans (previously called IVA femur), SF Femur scans
University Health Network, Toronto
Atypical Femur Fracture
12/24
12/25
NCT01155232: Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis

Recruiting
N/A
100
Canada
Teriparatide, Teriparatide is a section of the parathyroid hormone (PTH) given by injection., The drug is marketed by Eli Lilly under the name of Forteo
University Health Network, Toronto
Osteoporosis
01/25
01/26
NCT01747291: Atypical Fracture Cohort Study

Recruiting
N/A
300
Canada
University Health Network, Toronto
Atypical Femur Fracture, Atypical Subtrochanteric Fracture, Osteoporosis With AFf
12/25
12/26
NCT04110795: Personalizing Osteoporosis Care: Clinical & Genetic Risk Factors for AFFs

Active, not recruiting
N/A
1200
Canada
No Intervention
University Health Network, Toronto, Canadian Institutes of Health Research (CIHR)
Atypical Femur Fracture
12/25
12/27
NCT05541432: Finding the Optimal Resistance Training Intensity For Your Bones

Recruiting
N/A
324
Canada
Supervised strength training (group 1), Supervised strength training (group 2), Home exercise
University of Waterloo, Canadian Institutes of Health Research (CIHR), University of Saskatchewan, University Health Network, Toronto
Osteoporosis, Osteopenia
09/26
09/26
CaNAL, NCT03569826: Canadian Network for Autoimmune Liver Disease

Recruiting
N/A
2500
Canada
Observational; no intervention
University Health Network, Toronto
Primary Bilary Cirrhosis (PBC), Autoimmune Hepatitis, Overlap Syndrome
12/28
12/28
Saal, Howard
PROPEL 2, NCT04265651 / 2019-002954-21: Study of Infigratinib in Children with Achondroplasia

Active, not recruiting
2
84
Europe, Canada, US, RoW
Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg, Infigratinib 0.064 mg/kg, Infigratinib 0.128 mg/kg, Infigratinib 0.25 mg/kg
QED Therapeutics, Inc.
Achondroplasia
10/24
12/24
NCT05231668: Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Terminated
1
16
Europe, Canada, US, RoW
SAR439459, Placebo
Sanofi
Osteogenesis Imperfecta
11/24
11/24
PROPEL, NCT04035811: Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

Recruiting
N/A
250
Europe, Canada, US, RoW
QED Therapeutics, Inc.
Achondroplasia
06/26
06/26
Jain, Mahim
NCT05231668: Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Terminated
1
16
Europe, Canada, US, RoW
SAR439459, Placebo
Sanofi
Osteogenesis Imperfecta
11/24
11/24
NCT05317637: Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708

Recruiting
N/A
18
US
Baylor College of Medicine
Osteogenesis Imperfecta
08/25
09/26
NCT02432625: BBD Longitudinal Study of Osteogenesis Imperfecta

Recruiting
N/A
1000
Canada, US
Baylor College of Medicine, Shriners Hospitals for Children, Hospital for Special Surgery, New York, Children's National Research Institute, Hugo W. Moser Research Institute at Kennedy Krieger, Inc., University of California, Los Angeles, Oregon Health and Science University, University of Nebraska, Alfred I. duPont Hospital for Children, University of South Florida, Phoenix Children's Hospital, Marquette University
Osteogenesis Imperfecta
08/25
12/26
Ho, Irene
NCT05231668: Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Terminated
1
16
Europe, Canada, US, RoW
SAR439459, Placebo
Sanofi
Osteogenesis Imperfecta
11/24
11/24
Nguyen, Dianne
NCT05231668: Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Terminated
1
16
Europe, Canada, US, RoW
SAR439459, Placebo
Sanofi
Osteogenesis Imperfecta
11/24
11/24
NCT02432625: BBD Longitudinal Study of Osteogenesis Imperfecta

Recruiting
N/A
1000
Canada, US
Baylor College of Medicine, Shriners Hospitals for Children, Hospital for Special Surgery, New York, Children's National Research Institute, Hugo W. Moser Research Institute at Kennedy Krieger, Inc., University of California, Los Angeles, Oregon Health and Science University, University of Nebraska, Alfred I. duPont Hospital for Children, University of South Florida, Phoenix Children's Hospital, Marquette University
Osteogenesis Imperfecta
08/25
12/26

Download Options